Table 3.

Associations between statin exposure based on solubility and breast cancer incidence in the NHS, among new initiators of statins 2004–2012

Cases, nAge-adjusted HR (95% CI)Multivariatea HR (95% CI)
All invasive cases (n = 1,337)
Lipophilic statins
 Never user of any statin8491.0 (ref)1.0 (ref)
 Former users761.1 (0.84–1.4)1.0 (0.79–1.3)
 Current users1851.2 (1.0–1.4)1.1 (0.94–1.3)
Hydrophilic statins
 Never user of any statin8491.0 (ref)1.0 (ref)
 Former users901.1 (0.89–1.4)1.1 (0.84–1.3)
 Current users1011.1 (0.89–1.4)1.0 (0.81–1.3)
Invasive ductal carcinoma (n = 802)
Lipophilic statins
 Never user of any statin5151.0 (ref)1.0 (ref)
 Former users401.1 (0.79–1.5)0.99 (0.71–1.4)
 Current users941.1 (0.90–1.4)1.0 (0.82–1.3)
Hydrophilic statins
 Never user of any statin5151.0 (ref)1.0 (ref)
 Former users350.94 (0.66–1.4)0.87 (0.60–1.3)
 Current users631.1 (0.87–1.5)1.0 (0.79–1.4)
Invasive lobular carcinoma (n = 123)
Lipophilic statins
 Never user of any statin761.0 (ref)(not estimable)
 Former users60.91 (0.39–2.1)
 Current users161.2 (0.70–2.1)
Hydrophilic statins
 Never user of any statin761.0 (ref)(not estimable)
 Former users60.83 (0.35–2.0)
 Current users90.99 (0.49–2.0)
ER-positive cases (n = 919)
Lipophilic statins
 Never user of any statin5811.0 (ref)1.0 (ref)
 Former users451.0 (0.75–1.4)0.94 (0.69–1.3)
 Current users1071.1 (0.90–1.4)1.0 (0.83–1.3)
Hydrophilic statins
 Never user of any statin5811.0 (ref)1.0 (ref)
 Former users440.95 (0.69–1.3)0.91 (0.66–1.3)
 Current users711.1 (0.86–1.4)1.0 (0.79–1.3)
ER-negative cases (n = 168)
Lipophilic statins
 Never user of any statin1071.0 (ref)1.0 (ref)
 Former users121.6 (0.85–2.9)1.5 (0.78–2.7)
 Current users241.4 (0.88–2.2)1.3 (0.83–2.1)
Hydrophilic statins
 Never user of any statin1071.0 (ref)1.0 (ref)
 Former users70.93 (0.42–2.1)0.86 (0.38–2.0)
 Current users131.1 (0.62–2.0)1.0 (0.56–1.9)
In situ cases (n = 210)
Lipophilic statins
 Never user of any statin1361.0 (ref)(not estimable)
 Former users90.98 (0.49–2.0)
 Current users251.2 (0.77–1.8)
Hydrophilic statins
 Never user of any statin1361.0 (ref)(not estimable)
 Former users80.97 (0.46–2.1)
 Current users140.99 (0.56–1.8)
  • aAdjusted for body mass (continuous), first-degree family history of breast cancer (dichotomous), personal history of BBD (dichotomous), parity and age at first birth (design variables: see categories in Materials and Methods), age at menarche (<12, 12–13, or 14+), cumulative average ethanol consumption (design variables: see categories in Materials and Methods), MHT use (design variables: see categories in Materials and Methods), prevalent diabetes, and concomitant use of aspirin, ibuprofen, preventive tamoxifen, beta-blockers, calcium channel blockers, ACE inhibitors, and digoxin.